Introduction
The zinc-dependent membrane alanyl-aminopeptidase [aminopeptidase N (APN)/CD13] exhibits ectopeptidase activity by hydrolyzing oligopeptides with a preference to neutral amino acids. APN expression is widely distributed and has been found on different epithelial and endothelial cells, haematopoietic cells and also on tumours of distinct origin (1) . APN expression is controlled at the transcriptional level by two distinct promoters and an enhancer region between both DNA sequences. The epithelial or proximal promoter is arranged directly upstream from the start codon and is predominantly active in epithelial of the intestine, liver and kidneys as well as in endothelial cells, whereas the myeloid promoter is located about 8 kb upstream of the ATG initiation codon and is active in myeloid haematopoietic cells and fibroblasts (2, 3) .
Concerning its physiological function, APN is involved in various cellular processes, including the modulation of immune responses, inflammation, cell cycle control, cell differentiation and motility, angiogenesis as well as cellular attachment (reviewed in ref. 4, 5) . In addition, APN plays an important role in tumour biology, which is mainly attributed to the regulation of the local homeostasis of peptide hormone and growth factor activation (6) , thereby controlling cell proliferation, angiogenesis as well as promoting the metastatic progression of tumours (5) . APN expression levels are high in thyroid, lung cancer as well as in head and neck squamous cell carcinoma, which is associated with increased malignant behaviour and reduced overall survival rates (7) (8) (9) . In contrast, a reduced APN expression pattern was found in a number of tumour types, including high-grade meningiomas, renal and prostate carcinoma (10) (11) (12) (13) (14) .
Regarding APN in melanoma progression, Elder et al. (15) first described the expression of the 452 antigen later identified as APN in melanoma cells but not in melanocytes. Employing microbial aminopeptidase inhibitors as well as blocking antibodies, APN was characterized to exhibit important functions in invasion, extracellular matrix degradation and angiogenic processes during melanoma progression (16) (17) (18) (19) . Furthermore, APN-transfected melanoma cells demonstrated an enhanced migratory capacity, an increased degradation of type IV collagen as well as a higher frequency in the generation of lung metastases in nude mice when compared with APN-negative control cells (20) .
So far, the molecular mechanisms of altered APN expression and the clinical relevance of its expression in melanoma have not yet been elucidated in detail. In this study, we show for the first time that APN expression is regulated by differential CpG methylation of its myeloid DNA promoter not only in melanoma cell lines but also in different melanoma lesions.
Materials and methods

Cell lines and tissues
The human melanoma cell lines were obtained from ESTDAB (http://www. ebi.ac.uk/ipd/estdab/) and were kindly provided by Graham Pawelec (University of Tübingen, Germany). APN-overexpressing melanoma cells were generated by transfection similar as described previously (21) . THP-1 and Jurkat cells were purchased from DSMZ (Braunschweig, Germany). All cell lines were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 10 mM N-2-hydroxyethylpiperazine-N#-2-ethanesulfonic acid and respective antibiotics. Fresh tumour cell suspensions were obtained from surgical specimens by mechanical/enzymatic digestion and stored in liquid nitrogen until use (termed T1-13). Short-term melanoma cultures of single-cell suspensions (termed C1-18) were grown under standard conditions as described previously (22) . The study was approved by the Institutional Ethics Committee and assigned and conducted according to the Helsinki Declaration.
Treatment of cells
For demethylation studies, cell lines were treated every day in fresh medium with different concentrations (0-10 lM) of 5-aza-2#-desoxycytidine (DAC; Sigma, St Louis, MO) for the time-points indicated. For investigating APN regulation by cytokines, recombinant cytokines were supplemented on days 3 and 4 of DAC treatment with the following concentrations: 100 ng/ml basic fibroblast growth factor (bFGF; Cell Signaling, Danvers, MA), 10 ng/ml transforming growth factor b1 (TGF-b1; R&D Systems, Minneapolis, MN), 100 U/ml interleukin (IL)-4 (eBioscience, San Diego, CA), 100 U/ml IL-6 (Pan Biotech, Aidenbach, Germany) as well as 50 ng/ml epidermal growth factor (EGF; Cell Concepts, Umkirch, Germany). Blocking of APN enzyme activity was performed by treating the cells with 100 lg/ml of the APN-specific antibody WM15 (BD Biosciences, Heidelberg, Germany) as well as with 200 lM of the microbial aminopeptidase inhibitors bestatin or actinonin (both purchased from Sigma), respectively.
Silencing of APN expression
A total of 1 Â 10 5 melanoma cells were seeded into six-well plates, 1 day later transfected with small interfering RNA targeting APN (NM_001150, CCACACUGGUCAAUGAGGCUGACAA) as well as with unspecific nonsilencing control small interfering RNA (Invitrogen, Karlsruhe, Germany) using the Lipofectamine 2000 reagent (Invitrogen) according to manufacturer's instructions. After 2 days, transfection was repeated, cells were incubated for additional 48 h in complete RPMI 1640 medium and then harvested for RNA and protein analysis.
PCR analysis
RNAs from short-term melanoma cultures were isolated by using the mirVana miR isolation kit (Ambion, Austin, TX). Total cellular RNA of melanoma cells were isolated and reverse transcribed into complementary DNA as recently described (21) . End-point reverse transcription-PCR (RT-PCR) was performed with Taq DNA polymerase (Invitrogen) and respective primers (Supplementary Table 1 is available at Carcinogenesis Online) using standard protocols. Real-time quantiative RT-PCR was performed and evaluated on a Rotor-Gene 6000 system (Corbett Research, Sydney, Australia) employing the Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen). Messenger RNA (mRNA) levels were normalized to that of peptidylprolyl isomerase A. All quantitative RT-PCR analyses were performed using RNA from at least three independent experiments.
Flow cytometry
In total, 5 Â 10 5 cells were stained with the phycoerythrine-conjugated APNspecific monoclonal antibody (mAb) Leu-M7 and with the appropriate mouse IgG1 phycoerythrine control (both purchased from BD Biosciences) at room temperature in the dark for 20 min. After fixation with 2% (wt/vol) paraformaldehyde for 10 min and two washing steps, fluorescence intensity was determined on a FACS can flow cytometer using the CellQuest software (BD Biosciences). The results are presented in histograms of a representative staining with mean fluorescence intensity values of at least three independent experiments. For cytokine stimulation experiments, the isotype-corrected mean fluorescence intensity values of stimulated cells were divided with the values of untreated cells. Data represent average of at least three independent experiments.
Western blot analysis
Protein expression studies were performed as described previously (21) . Briefly, 50 lg total protein per lane were separated in 8% sodium dodecyl sulphatepolyacrylamide gel electrophoresis, transferred to nitrocellulose membrane and immunoblotted with anti-green fluorescent protein pAb or anti-APN mAb (both purchased from Santa Cruz Biotechnology, Santa Cruz, CA). Equal protein loading was determined using an anti-b-actin mAb (Abcam, Cambridge, UK). After incubation with appropriate horseradish peroxidase-conjugated secondary antibodies, protein bands were detected using a chemiluminescence-based system.
Analysis of the methylation status
The existence and number of CpG oligonucleotides in the myeloid APN promoter was determined and further mapped by MethPrimer (23) . Bisulfite-specific primers (Supplementary Table 1 is available at Carcinogenesis Online) flanking 52 CpG sites in the myeloid APN promoter 600 bp upstream of the transcription start were designed. Genomic DNA from established melanoma cell lines was isolated using the QIAamp DNA Mini Kit, from short-term melanoma cultures as well as suspension of melanoma lesions using the DNeasy Blood and tissue Kit (both obtained from Qiagen, Hilden, Germany). Two micrograms of genomic DNA were subjected to bisulfite modification with the EpiTect Bisulfite Kit (Qiagen) according to the manufacturer's protocol. After nested PCR amplification, the methylation status of the myeloid APN promoter was analysed by combined bisulfite restriction analysis (COBRA) as well as DNA sequencing. For COBRA, 50 ng of the resulting amplification products were digested with the restriction enzymes BsrBI, BstUI, Taq a I, RsaI or Hpy188I recognizing CG sequences (New England BioLabs, Frankfurt, Germany) prior to separation on 3% agarose gels. For bisulfite genomic sequencing, the nested PCR products were gel-purified and either directly subjected to sequence analysis by a commercially available service provider or cloned into the pCR2.1-Topo vector using the TOPO TA Cloning Kit (Invitrogen). From 10 randomly selected bacterial colonies, DNA was purified using QIAprep Spin Miniprep Kit (Qiagen) and then sequenced.
Soft agar cloning and growth curve analysis
The anchorage-independent growth of melanoma cells was determined by plating 3 Â 10 4 cells in 0.3% soft agar on top of a 0.5% agar base layer, both prepared with 20% fetal bovine serum-supplemented RPMI 1640 medium. The soft agar culture plates were cultivated in a humified CO 2 incubator for 3 weeks. Vital cells were staining with iodo-nitrotetrazoliumchloride overnight and soft agar colonies were digitalized.
For analysis of the proliferation rate, 2 Â 10 4 cells were seeded into six-well plates and incubated at 37°C and 5% CO 2 . The cell number was determined in duplicates every day over a period of 5 days. The doubling time was calculated using the standard formula. The data are represented as the mean of at least three independent experiments.
Migration assay
The migration of APN-negative versus APN-expressing melanoma cell lines was analysed as recently described (21) . Briefly, 2.5 Â 10 5 cells were seeded in the transwell insert and 10 lg/ml collagen type I (BD Biosciences) as chemoattractant were added to the lower chamber. Cells were allowed to migrate for 22 h at 37°C in the absence or presence of APN inhibitors. Migrated cells were quantified using the Cell-Titer-Glo Luminescent Cell Viability Assay (Promega, Madison, WI) according to the manufacturer's protocol. Results are presented as percentage of migrated cells in relation to the total cell number used in the assay.
Tissue microarray
Tissue microarrays (TMAs) generated as described previously (24) were obtained from the archives of the Department of Dermatology, University of Regensburg, Regensburg, Germany. TMAs contained a total of 465 formalinfixed, non-selected, consecutive paraffin-embedded human tissues from patients with benign melanocytic nevi, malignant melanoma and metastases. One tissue core per specimen with a diameter of 0.6 mm was punched out of the donor block and transferred to the recipient block. In patients with multiple subsequent neoplasms, only initial and unifocal malignant melanomas were included. Haematoxylin and eosin-stained slides of all tumours were evaluated by two dermatopathologists (P.W. and K.I.). Clinical follow-up data provided by the Central Tumor Registry, Regensburg, Germany were available for all patients with primary malignant melanoma. In the group of patients with primary melanoma, the patients' age ranged from 22 to 94 years (median 61 years). The median follow-up for all patients with malignant melanoma was 51 months (range 0-186 months). Median follow-up time of censored patients was 52 months (range 1-186 months). A total of 12.9% of patients died of melanoma disease during follow-up after a median time of 26 months (range 0-154 months).
Immunohistochemistry
Paraffin-embedded preparations of tissues from patients with benign melanocytic nevi, primary melanoma and melanoma metastases were screened for APN protein expression by immunohistochemistry. The TMA blocks were freshly cut (3 lm) and mounted on superfrost slides (Menzel-Glaeser, Braunschweig, Germany). In brief, tissues were deparaffinised, rehydrated and subsequently incubated with primary antibody overnight at 4°C. Immunohistochemistry was conducted with the Ventana Benchmark automated staining system (Ventana Medical Systems, Tucson, AZ) using Ventana reagents for the entire procedure. The following primary antibodies were used: anti-APN mAb (clone 38C12, dilution 1:100; Novocastra Laboratories Ltd., Newcastle upon Tyne, UK) and anti-Ki-67 mAb (clone MIB-1, dilution 1:100; Dako, Hamburg, Germany). The primary mAbs were detected with the ultraView Universal Alkaline Phosphatase Red Detection Kit (Ventana Medical Systems). Slides were counterstained with haematoxylin, dehydrated and mounted.
A surgical pathologist (K.I.) performed a blinded evaluation of the stained slides. Samples were grouped into negative and positive APN expression, respectively. Positive immunoreactivity was defined if at least faint staining could be observed. The Ki-67 proliferation rate was defined as percentage of positive nuclei as recently described (25) . High Ki-67 labelling index was defined if at least 5% of the tumour cells were positive. Causes of non-interpretable results included either lack of tumour tissue or presence of necrosis or crush artefacts.
Statistical analysis of TMA data
Contingency table analysis, two-sided chi-square and Fisher's exact tests were used to study the statistical association between clinico-pathological and immunohistochemical parameters of the TMA. Retrospective overall survival and recurrence-free survival (RFS) were defined as clinical end-points. Survival curves comparing patients with or without any of the factors were calculated using the Kaplan-Meier method, with significance evaluated by two-sided log-rank statistics. For the analysis of RFS, patients were censored at the time of their last tumour-free clinical follow-up appointment. RFS data were only available for 226 patients (62%) with a median follow-up time of 18 months (range 1-142 months). For analysis of overall survival, patients were censored at the time of their last clinical follow-up appointment or at their date of death not related to the tumour. P values ,0.05 were considered significant. Statistical analyses were completed using SPSS version 17.0 (SPSS, Chicago, IL). In case of multiple statistical tests, the Bonferroni-Holm method was used. The University of Regensburg institutional review board granted approval for the project. Concerning other experimental results, the data are expressed as mean ± standard error of the mean. Statistical analyses were calculated by student's test.
Results
Characterization of APN-expressing melanoma cell lines
Melanoma progression from benign melanocytes to malignant tumour is a multi-phase process accompanied with many cellular and J.Wulfänger et al. molecular changes, e.g. down-regulated expression of melanocytic marker, epithelial to mesenchymal transition, cadherin-switch and differential cytokine secretion (reviewed in ref. 26, 27) . To characterize the cell lines used in this study, the APN mRNA of melanocyte samples and 17 different melanoma cell lines was first quantified using quantitative RT-PCR and compared with the protein expression data obtained with flow cytometry ( Figure 1A ). Despite detectable APN transcription in all cell lines, only seven melanoma lines with high mRNA levels exhibited a directly correlated APN protein surface expression (APN þ ). The other melanoma cell lines lacked APN protein as exemplarily shown for the APN-negative cell line WM-1862. APN protein positivity was correlated with a down-regulated expression of melanocytic markers, such as gp100, MART-1, S100B and tyrosinase (Figure 1B; Supplementary  Table 2 is available at Carcinogenesis Online). Furthermore, decreased mRNA amounts of the microphthalmia-associated transcription factor, which is involved in the regulation of these markers, were determined in APN þ compared with APN-negative melanoma cell lines ( Figure 1B ; Supplementary Figure 1A is available at Carcinogenesis Online).
Former in vitro transfection or inhibitor studies demonstrated that APN expression is accompanied with a more aggressive behaviour of melanoma cells in comparison with APN-negative controls (19, 20, 28) . In order to clarify the APN function in our system, the growth and migration properties of APN-negative cells were compared with those of APN þ melanoma cell lines. Since the doubling time and the number of soft agar colonies of APN-negative and APN þ melanoma cell lines were comparable, APN expression did neither affect the in vitro proliferation nor the anchorage-independent growth of melanoma cells (Supplementary Figure 1B is available at Carcinogenesis Online). In contrast, APN þ melanoma cells exhibited an increased migration capacity to collagen using the transwell system varying from 30 to 60% compared with $12% in APN-negative melanoma cells ( Figure 1C ). This increase could be blocked by the aminopeptidase inhibitors bestatin and actinonin or by APN-specific small interfering RNA, whereas APN overexpression into APN-negative WM-1862 cells resulted in an enhanced motility when compared with parental cells and vector controls ( Figure 1D ) confirming the functional role of APN in melanoma migration.
DNA methylation of the myeloid APN promoter Differential gene expression of various proteases is described to be accompanied with the development and progression of cutaneous malignant melanoma (reviewed in ref. 29) , which is often shown to be associated with epigenetic changes. To the best of our knowledge, using a bioinformatic program we have identified for the first time a putative CpG island in the myeloid APN promoter, which consists of 123 CpG sites within a 1.3 kb DNA sequence (Figure 2A ). By the way using this program, no CpG islands could be found in the epithelial promoter as well as in the transcriptional enhancer region of APN (Supplementary Figure 2A is available at Carcinogenesis Online).
Using two different primer sets discriminating myeloid mRNA from total APN mRNA amounts in end-point PCR analysis, high mRNA levels were generated from the myeloid promoter in APN þ but not in APN-negative cells ( Figure 2B ). To investigate whether DNA hypermethylation of the myeloid promoter could be involved in the regulation of APN expression, bisulfite-treated DNA of APNnegative and APN þ melanoma cells was subjected to PCR with primers amplifying a 412 bp long sequence containing 32 CpG sites directly located upstream of the transcription start of the myeloid APN promoter. Applying bisulfite sequencing, heterogeneous promoter DNA methylation was observed in the different cell lines. APN þ melanoma cells exhibited a significantly reduced methylation status in comparison with APN-negative melanoma cells (P , 0.001). Whereas in APN þ cells the frequency of methylated CpG sites at position 1-15 varied between 0 and 40.6%, APN-negative cells exhibited a total methylation at the same positions ( Figure 2C ). In addition, the overall methylation frequency was increased to 54.7-92.2% with a distribution over all 32 CpG oligonucleotides analysed (Supplementary Table 2 is available at Carcinogenesis Online). These sequencing data were confirmed by COBRA for all melanoma cell lines and melanocytes on several CpG oligonucleotides ( Figure 2D ; Supplementary Figure 2B is available at Carcinogenesis Online). The human leukaemic monocytic cell line THP-1 exhibiting an APN expression comparable with WM-1552C served as a control and completely lacked CpG methylation. In contrast, in the human APN-negative T cell line Jurkat a high number of methylated CpG sites was found in the myeloid APN promoter, indicating that the extent of APN promoter DNA methylation was associated with lack of APN protein expression independent of the cell type analysed.
Demethylation induces APN expression and function
Both APN-negative as well as APN þ melanoma cell lines were treated with various concentrations of the demethylating reagent DAC for various time-points before APN expression studies were performed. Whereas DAC had no effect on APN þ GR-M cells, enhanced APN mRNA levels varying from 6.4-to 67.3-fold (Supplementary Table 2 is available at Carcinogenesis Online) as well as an increased transcriptional activity of the myeloid promoter were detected in APNnegative melanoma cell lines upon this treatment ( Figure 3A ). These were accompanied by an induction of APN surface expression as representatively demonstrated for four APN-negative melanoma cell lines ( Figure 3B ). The DAC-mediated changes of APN mRNA and protein levels were time-and dose-dependent (see Supplementary  Figure 3 , available at Carcinogenesis Online). Prolonged cultivation of cells in medium without DAC for 4 days further increased APN surface expression of APN-negative melanoma cells ( Figure 3B ). DAC treatment also caused a decreased proliferation rate of all melanoma cell lines analysed independent of the APN expression status ( Figure 3C ). In contrast, restored APN expression in APN-negative melanoma cells was associated with increased migration rates, which could be blocked to $50% using the APN-specific antibody WM15 suggesting a direct link between APN and migration ( Figure 3D ).
Restoration of cytokine-stimulated APN expression after DAC treatment Several cytokines have been shown to regulate APN expression in different cell types, e.g. IL-4 increases APN expression in monocytes, endothelial cells and renal cell carcinoma cells (30, 31) . To investigate an association of APN expression and cytokine production in melanoma cells, the mRNA expression of five cytokines known to control either APN expression or to be involved in melanoma progression was analysed. Whereas EGF and IL-4 transcripts were heterogeneously expressed without any link to APN expression, the mRNA levels of bFGF, TGF-b1 and IL-6 were higher in APN þ melanoma cells compared with APN-negative melanoma cells (Supplementary Figure 4 is available at Carcinogenesis Online).
In order to determine whether these cytokines can up-regulate APN expression in melanoma, APN þ WM-1552C and GR-M cells were stimulated for 48 h before APN quantitation. TGF-b1 and IL-4 causes an increase in APN transcription ( Figure 4A ) and in protein expression, exemplarily shown for GR-M in Figure 4B , whereas bFGF, IL-6 and EGF do not regulate APN expression. Then, APN-negative Colo-794 cells were treated with these cytokines in the presence or absence of DAC. As shown in Figure 4C , not the cytokine treatment alone, but a combination of cytokine with demethylation induces myeloid APN transcripts, suggesting an inhibitory effect of the APN promoter DNA methylation on the cytokine-mediated stimulation. The highest APN protein surface expression with an up to 2-fold increase were found after co-incubation of DAC with TGF-b1 or IL-4 ( Figure 4D ). In contrast, bFGF, IL-6 or EGF exerted no or only a marginal additive effect on the activity of the myeloid promoter. These observations could be confirmed with the APN-negative cell line Colo-857 (data not shown).
Differential DNA methylation of the myeloid APN promoter in primary melanoma
To investigate the influence of promoter DNA methylation on APN gene expression in melanoma lesions, the amount of myeloid as well 
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as of total APN transcripts of 18 short-term cultures of melanoma lesions (C1-C18) were compared with the methylation status of the myeloid APN promoter analysed by COBRA ( Figure 5A and B) . High expression of APN transcripts was associated with a low frequency of APN promoter DNA methylation, whereas no or marginal APN expression correlated with a high degree of methylated CpG oligonucleotides (P , 0.001). To assess the methylation status of this chromosomal DNA region, three tumours with different APN expression levels were selected and subjected to DNA sequencing of 10 individual bacterial clones as described in Materials and methods. As shown in Figure 5C , APN expression was dependent on the methylation status of the myeloid APN promoter also in melanoma lesions (P 5 0.023). Whereas C7 with the highest APN expression was marginally methylated, a higher degree of methylation was found in the tumour probe C5 with medium APN expression. Methylation was even more pronounced in the APN-negative tumour probe C4. The highest frequency of methylated CpG oligonucleotides was detected in CpG position 1-11, which was analogous to the results obtained by direct sequencing of the melanoma cell lines. Similar to the data in melanoma cell lines, high APN levels were also associated with a decreased expression of melanocytic markers in these primary tumours (Supplementary Table 3 is available at Carcinogenesis Online). In addition, a heterogeneous methylation pattern of the APN promoter DNA was detected in 13 fresh tumour cell suspensions (T1-13, without any in vitro culture), indicating that no culture artefact was responsible for the differences in the APN promoter DNA methylation ( Figure 5D ).
APN protein expression in a melanoma TMA
To study APN expression in a high number of patient tissues, TMA consisting of 364 primary malignant melanoma lesions, 39 metastases and 62 benign nevi including compound and dermal nevi was stained with an APN-specific mAb. Fifty-eight tissues of total 404 cases exhibited at least a weak membranous and cytoplasmic APN staining. Thereby, primary melanoma showed a higher APN expression (16.9%) when compared with benign nevi (4.1%) and melanoma metastases (5.7%) (P , 0.001; Figure 6A ). Higher Clark levels, increased tumour thickness .2.0 mm and positive nodal status (pN1-3) were significant prognostic factors (Supplementary Table 4 is available at Carcinogenesis Online). However, there existed neither a significant correlation of APN positivity with these factors (Supplementary Table 5 is available at Carcinogenesis Online) nor with C7 and C12 as short-time melanoma cultures with the highest APN expression were both histologically typed as nodular melanoma. This subtype showed the shortest overall survival of all indicated melanoma kinds in the TMA ( Figure 6B ). However, no association was found for APN positivity with either nodular melanoma or with any of the other subtypes ( Figure 6C ).
Discussion
APN exerts many biological functions, such as processing biologically active peptides, promotion of invasion and degradation of extracellular matrices as well as modulation of cell motility and angiogenesis (6) . Despite an altered APN expression has been described in several tumour types, limited information exists with respect to the regulation mechanism of its gene expression in tumours. A transcriptional control of APN by different transcription factors, such as c-Myb, Ets-2 or c-Maf has been demonstrated in endothelial cells (32) (33) (34) . Several cytokines are known to up-regulate APN protein expression in different cell types (30, 31, 35) . Furthermore, cell-cell contacts as well as hypoxia have been discussed as factors involved in APN regulation (4, 36) . With respect to other membrane peptidases often co-localized with APN, an epigenetic control has been described. For example, CpG methylation was detected for the neprilysin/CD10 in lymphoid malignancies and in prostate carcinoma, for dipeptidyl peptidase IV/CD26 in T-cell leukaemia and melanoma (37) (38) (39) (40) . Since similar data on APN are lacking and a putative CpG island is located in the myeloid APN promoter, methylation-specific PCR and bisulfite sequencing were used by us to determine the DNA methylation status of the myeloid APN promoter in primary and established melanoma cell lines as well as in melanoma lesions. We here show for the first time that (i) the myeloid APN promoter indeed contains a large CpG island; (ii) low CpG methylation frequency is accompanied with higher levels of myeloid promoter-derived APN mRNA as well as protein; (iii) DAC-mediated demethylation restores protein expression, which was accompanied by an enhanced migration and (iv) these observations are not limited to cell lines but can also be extended to short-term tumour cultures as well as melanoma lesions indicating an in vivo relevance of DNA methylation controlling APN expression. Additionally, we could also observe a differential DNA methylation in cells of haematopoietic origin as demonstrated for THP-1 and Jurkat cells. Thus, epigenetic silencing of APN and other aminopeptidases might represent a common mechanism not only in melanoma but also in other tumour or non-tumorous cells to regulate their expression.
In the melanoma cell lines investigated a broad range of DNA methylation of the myeloid APN promoter was observed. Several APN protein-expressing cell lines have clearly demethylated CpG sites compared with the strongly methylated regions of APN-negative cells. As described in literature, melanocytes lack APN expression (15, 16, 41) . In our analysis, the mRNA amounts and the semimethylated status of the myeloid APN promoter of melanocytes indicate that APN protein expression in these cells should be classified in between positive and negative when compared with the melanoma cells analysed. Interestingly, Seftor et al. (41) showed that a 4 day incubation of melanocytes in a matrix preconditioned by highly aggressive melanoma cells resulted in a reversible up-regulation of APN mRNA accompanied by VE-cadherin, urokinase, c-Met as proto-oncogene-encoding hepatocyte growth factor receptor protein and the laminin 5 c2 chain. These authors discussed an epigenetic transdifferentiation of the benign melanocytic phenotype by the microenvironment and APN expression might represent one link in the chronology of these phenotypic changes.
DNA methylation leads to a more compact chromatin structure of chromosomal promoter regions causing repression of gene activity by disturbing the binding of transcription factors (42) . Demethylation might be a precondition for the stimulatory effect of these cytokines on APN expression. Indeed, cytokines alone could not induce APN, but stimulation by recombinant IL-4 and TGF-b1 in combination with DAC restored APN protein expression. IL-4 is known to increase APN expression in monocytes and epithelial cells (30, 31) ; both APN promoters should be involved. In contrast, TGF-b1 increases APN expression on monocytes (35) and melanoma, whereas it has no APN promoter methylation in melanoma influence on renal or thyroid carcinoma (7, 31) . Therefore, the TGF-b1 effect might be selectively driven by the myeloid promoter dependent on tumour entities analysed. Interestingly, we found APN upregulated in melanoma cells after TGF-b1 treatment as well as a higher expression of this cytokine in APN þ compared with APN-negative melanoma. Increased expression of TGF-b has been observed in invasive primary melanomas and in metastatic nodules as compared with normal skin melanocytes (43) . Resistance to TGF-b-mediated tumour suppression in melanoma appears to be a crucial step in tumour aggressiveness since it is usually coupled with the ability of TGF-b to drive the oncogenic process via autocrine and paracrine effects (44) . Taken together, a dependence of CpG methylation density and the capability for cytokine stimulation is suggested by us and will be the focus of further studies.
Previous studies discuss APN as a marker of higher migration capacity and aggressiveness in melanoma (19, 20, 28) . Our in vitro results are in accordance with the literature since APN expression was associated with loss of melanocytic marker expression in cell lines as well as in tumour lesions. Furthermore, a 2-to 5-fold increased migration rate of APN 1 versus APN-negative melanoma cells was measured, which could be blocked by RNA interference or aminopeptidase-specific inhibitors. Treatment of APN-negative cells with the demethylating agent DAC could not only induce APN protein but also caused an APN-mediated increase of cell migration. DAC has been recently implemented into several clinical phase I trials and antitumour efficacy is currently monitored in different solid tumours. Almost all in vitro studies demonstrated that promoter demethylation using DAC decreases cell growth by induction of different tumour suppressor genes, but it might also activate silenced prometastatic genes like APN as demonstrated in this study. Consistent with our data, Ateeq et al. (45) described an induction of pro-invasive and pro-metastatic genes, e.g. the urokinase-type plasminogen activator, the chemokine receptor CXCR4 as well as the breast cancer-specific gene 1 leading to an increased invasion and migration ability of non-invasive breast cancer cell lines. Based on this knowledge, the implementation of demethylating agents in antitumour therapy of melanoma has to be further evaluated.
When data on the higher motility of APN þ melanoma cells are taken into account, an association of APN expression in melanoma tissues with worse patients' prognosis was postulated. However, our data of a TMA consisting of 465 human tissues, including benign melanocytic nevi, malignant melanoma and melanoma metastases did not show an association of APN expression and shorter patients' survival. APN protein could only be detected in 17% of all tumour samples analysed, in particular mainly in primary malignant melanoma. Another explanation would be APN expression as the property of a specific melanoma subtype. Winnepenninckx et al. (46) reported high levels of APN but diminished expression of melanocytic markers in 'spindle cell melanoma'. This subtype also known as desmoplastic melanoma represents ,2% of all melanoma. Unfortunately, we did not observe a significant association of APN staining with any melanoma subtype indicated. It is noteworthy that desmoplastic melanoma was not designated in the array employed. Additional factors might affect APN protein expression in vivo and these factors have to be elucidated yet.
In summary, we demonstrate for the first time that DNA methylation of the myeloid promoter regulates APN transcription in melanoma and that treatment with demethylating agents causes de novo APN protein expression in these cells leading to a migratory phenotype. Therefore, our findings provide a new principle controlling APN expression in cancer. Future studies will have to be extended to tumours of distinct origin to clarify whether epigenetic control is a common APN regulatory mechanism.
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